Senti Biosciences company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acq - Pending | Acquired

Total Raised




About Senti Biosciences

Senti Biosciences focuses on cell engineering and biological programming to develop therapeutics to solve challenging and complex diseases. The company has technology platforms to design synthetic gene circuits for adaptive cell and gene therapies.

Senti Biosciences Headquarter Location

2 Corporate Drive, First Floor

South San Francisco, California, 94080,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Senti Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Senti Biosciences is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Senti Biosciences Patents

Senti Biosciences has filed 9 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Cytokines, Immunology, Immune system, Interleukins


Application Date


Grant Date



Related Topics

Clusters of differentiation, Cytokines, Immunology, Immune system, Interleukins



Latest Senti Biosciences News

Senti Biosciences (SNTI) Surged 68.28%: Details You Should Know

Jul 31, 2022

The stock price of Senti Biosciences (SNTI) surged by 68.28% in the previous trading session. These are some details you should know. The stock price of Senti Biosciences (SNTI) surged by 68.28% in the previous trading session. There was no company-specific news report that drove up the stock price, but it’s worth mentioning that there was an uptick in discussions about the stock on social media platforms like Discord, StockTwits, Twitter, etc. It’s also worth mentioning that the company stock price fell by 25.88 after hours in the previous trading session as well. It appears that investors responded negatively to what was revealed in a regulatory filing. The regulatory filing said: “On July 26, 2022, Curt A. Herberts III, the Chief Operating Officer of Senti Biosciences, Inc., a Delaware corporation, notified the Company of his decision to resign from his employment with the Company, effective as of August 19, 2022.” Senti Biosciences debuted as a publicly traded company on June 9 after completing a business combination with special purpose acquisition company (SPAC) Dynamics Special Purpose Corp. The company is focused on gene circuit technology and generating promising data across lead programs SENTI-202 and SENTI-301. And the company is planning to advance toward IND filings in 2023. With the process proceeds raised from the public debut along with the cash on hand, the company should have enough to fund operations into 2024. Plus the proceeds from the transaction are expected to provide Senti Bio with capital to further develop its gene circuit technologies and therapeutic pipeline, including: — Conducting Investigational New Drug- (IND) enabling studies for SENTI-202 and SENTI-301 — Building out clinical-scale current good manufacturing practice (cGMP) capabilities and enabling cGMP runs for off-the-shelf CAR-NK cell therapies; Alameda, CA, facility startup on track for year-end 2022 — Filing IND applications for SENTI-202 and SENTI-301 in 2023 — Advancing SENTI-202 and SENTI-301 toward Phase 1/2 dose escalation clinical trials — Advancing its gene circuit platform with additional programs, such as SENTI-401 towards an anticipated IND filing in 2024, for solid tumors — Building out its gene circuit platform to expand modalities and therapeutic areas through potential collaborations and/or partnerships Trending on Pulse 2.0

Senti Biosciences Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Senti Biosciences Rank

  • When was Senti Biosciences founded?

    Senti Biosciences was founded in 2015.

  • Where is Senti Biosciences's headquarters?

    Senti Biosciences's headquarters is located at 2 Corporate Drive, First Floor, South San Francisco.

  • What is Senti Biosciences's latest funding round?

    Senti Biosciences's latest funding round is Acq - Pending.

  • How much did Senti Biosciences raise?

    Senti Biosciences raised a total of $158M.

  • Who are the investors of Senti Biosciences?

    Investors of Senti Biosciences include Dynamics Special Purpose, 8VC, Amgen Ventures, Lux Capital, New Enterprise Associates and 17 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.